Endo International plc (NASDAQ:ENDP) Given Consensus Rating of “Hold” by Analysts

Shares of Endo International plc (NASDAQ:ENDPGet Rating) (TSE:ENL) have earned a consensus recommendation of “Hold” from the eight analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $2.92.

ENDP has been the subject of a number of research reports. Piper Sandler downgraded shares of Endo International from a “neutral” rating to an “underweight” rating and decreased their price target for the stock from $3.00 to $1.00 in a research note on Friday, May 6th. TheStreet cut Endo International from a “c-” rating to a “d” rating in a research note on Wednesday, February 2nd. Citigroup dropped their price target on Endo International from $11.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, March 9th. Zacks Investment Research lowered Endo International from a “hold” rating to a “strong sell” rating and set a $2.50 price objective for the company. in a research report on Wednesday, February 9th. Finally, BMO Capital Markets dropped their target price on shares of Endo International from $4.00 to $2.00 in a report on Monday, May 9th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NorthCrest Asset Manangement LLC bought a new position in shares of Endo International during the first quarter valued at $28,000. First Quadrant LLC CA bought a new stake in Endo International during the 1st quarter valued at about $36,000. Nisa Investment Advisors LLC raised its holdings in Endo International by 500.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 18,000 shares of the company’s stock worth $57,000 after buying an additional 15,000 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of Endo International in the fourth quarter worth approximately $68,000. Finally, Carolina Wealth Advisors LLC grew its holdings in shares of Endo International by 20.2% during the first quarter. Carolina Wealth Advisors LLC now owns 29,862 shares of the company’s stock valued at $69,000 after buying an additional 5,028 shares during the last quarter. 80.39% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ENDP stock opened at $0.40 on Tuesday. Endo International has a fifty-two week low of $0.36 and a fifty-two week high of $7.07. The firm has a market cap of $93.11 million, a P/E ratio of -0.13 and a beta of 1.07. The business’s 50 day moving average price is $2.03 and its 200-day moving average price is $3.31.

Endo International (NASDAQ:ENDPGet Rating) (TSE:ENL) last announced its quarterly earnings results on Thursday, May 5th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.22. The company had revenue of $652.26 million during the quarter, compared to analyst estimates of $637.09 million. Endo International had a negative return on equity of 72.22% and a negative net margin of 24.82%. The firm’s revenue was down 9.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 earnings per share. On average, research analysts forecast that Endo International will post 0.79 EPS for the current fiscal year.

Endo International Company Profile (Get Rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

Featured Articles

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.